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Abstract 
We report the case of a primary nasopharyn-
geal  interdigitating  dendritic  cell  tumor
(IDDCT). A 25-year old male presented with
bilateral decreased hearing, double vision, and
ataxia. Flexible nasopharyngoscopy reviewed a
large mass obstructing and filling the entire
nasopharynx. MRI and PET-CT confirmed the
presence of the primary tumor and demonstrat-
ed bilateral cervical lymphadenopathy. Biopsy
of the nasopharynx revealed a hematolymphoid
neoplasm  with  dendritic  cell  differentiation,
most consistent with an IDDCT. The lesion was
unresectable.  The  patient  was  treated  with
definitive radiotherapy to 66 Gy to the primary
tumor and 50 Gy to the bilateral cervical lym-
phatics using an IMRT technique. A complete
response was achieved and the patient remains
disease free at the primary site 23 months after
completion of radiotherapy. 
Case Report
A  25-year  old  previously  healthy  African
American male presented with a one month
history of bilateral decreased hearing, double
vision, and ataxia. He was initially diagnosed
with vertigo and started on meclizine without
relief of symptoms. His symptoms progressed
rapidly over four weeks to include right-sided
facial weakness, sensation loss and decreased
taste. Physical examination revealed palsies of
the right cranial nerve VI, decreased sensation
in the right V3 branch of the trigeminal nerve,
right  cranial  nerve  VII.  Bilateral  middle  ear
effusions were present. Palpation of the neck
revealed a 6¥8 cm firm nodal mass in the left
level II-V cervical levels and a firm 2 cm right
level  II  lymph  node.  Flexible  fiberoptic
endoscopy  demonstrated  a  large  mass
obstructing and filling the entire nasopharynx. 
Staging radiographic findings
A head MRI was obtained. T1 post-contrast
sequences showed a lobulated and heteroge-
neously  enhancing  mass  with  regions  of
necrosis filling the nasopharynx extending to
the clivus and along the right carotid canal to
involve  the  right  cavernous  sinus,  Meckel's
cave  and  the  adjacent  tentorial  dura.
Pathologically enlarged bilateral lymph nodes
were seen, some of which demonstrated het-
erogeneous  T2  signal  hyperintensity  and  T1
hypointensity suggestive of necrosis. A whole
body PET-CT scan (Figure 1) revealed a hypo-
dense  mass  in  the  right  nasopharynx  with
increased  18F-fluorodeoxy-glucose  (FDG)
uptake with a maximum standard uptake value
(SUV)  of  11.7  and  an  average  SUV  of  9.4.
Additionally,  bilateral  palpable  cervical
adenopathy contained increased FDG uptake
with  maximum  SUVs  ranging  from  5.5-10.1
and average SUVs of 4.7-8.6. The patient was
staged  with  a  T4B,  N3B,  M0,  stage  IVB,
nasopharyngeal malignancy according to the
AJCC Edition 6 staging guidelines. 
Pathological findings
The patient was taken to the operating room
for direct nasopharyngoscopy with biopsy. The
operative findings demonstrated a large exo-
phytic and necrotic mass in the nasopharynx.
Histology demonstrated a diffuse infiltrate of
large  pleomorphic  cells  with  moderate
eosinophilic cytoplasm, folded nuclei and occa-
sionally  prominent  nucleoli.  Mitotic  figures
were easily identified and there were areas of
necrosis present. There was a background of
small  lymphoid  cells.  Immunohistochemical
stains  of  the  neoplastic  cell  population
revealed the tumor to be CD43 and S100 posi-
tive,  CD45  weakly  positive,  and  CD68  and
myeloperoxidase had focal weak positivity. All
other stains including CD3, CD4, CD5, CD7,
CD56, TIA-1, UCHL-1, CD30, Alk1, CD19, CD20,
CD21,  4KB5,  CD31,  CD34,  CD35,  lysozyme,
Leder, melA, HMB45, keratin, EBER and c-kit
were  negative.  Gene  rearrangement  studies
were performed showing no evidence of clonal
immunoglobulin heavy chain gene rearrange-
ment but there was a peak suggestive of a T-
cell  receptor  gamma  chain  gene  rearrange-
ment. The neoplasm was classified as a hema-
tolymphoid neoplasm with dendritic cell differ-
entiation, most consistent with an interdigitat-
ing dendritic cell tumor (IDDCT) (Figure 2).
Initial therapeutic intervention
The patient was started on oral dexametha-
sone 2 mg twice daily for a period of one week
followed  by  a  three  week  taper.  His  cranial
neuropathies resolved completely within a few
days.  The  patient  underwent  Image  Guided
Intensity  Modulated  Radiation  Therapy  (IG-
IMRT)  on  a  Hi-Art  Helical  TomoTherapy
(Madison, WI) unit. The target volume includ-
ed  the  gross  disease  in  the  skull  base,
nasopharynx,  the  bilateral  cervical  lymph
nodes and the retropharyngeal lymph nodes,
and  was  prescribed  50  Gy  in  25  fractions
(Figure 3). The patient had a complete clinical
response. A repeat MRI scan obtained after the
initial 50 Gy demonstrated an 80% decrease in
the size of the primary tumor and nodal dis-
ease. An additional 16 Gy in 8 fractions was
prescribed to the initial extent of primary and
nodal disease for a total dose of 66 Gy delivered
in 33 fractions over a course of 6.5 weeks. The
patient tolerated the treatment well but devel-
oped grade 2 nausea requiring anti-emetics,
and  grade  2  radiation-induced  xerostomia,
mucositis, and dermatitis. One month follow-
ing radiation the patient was started on sys-
temic  chemotherapy  with  ifosphamide  (5
mg/m
2),  carboplatin  (AUC  5)  and  etoposide
(100 mg/m
2) and mesna (5 mg/m
2), receiving a
total of 4 cycles. He also received central nerv-
ous system (CNS) prophylaxis with intrathecal
methotrexate (12 mg) for a total of 3 cycles.
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Radiographic response assessment
A repeat whole body PET-CT scan obtained
one month after completion of external beam
radiotherapy  and  prior  to  chemotherapy
(Figure  1)  revealed  only  a  small  residual
nasopharyngeal  volume  with  increased  FDG
uptake  with  a  maximum  SUV  uptake  of  4.8
compared to 11.7 pre-treatment. There was no
evidence of abnormal FDG uptake in the bilat-
eral  cervical  lymphatics  or  elsewhere.  Five
months  after  completion  of  external  beam
radiotherapy and one month after completion
of systemic chemotherapy a repeat PET-CT was
obtained.  There  was  persistent  soft  tissue
thickening in the region of the nasopharynx
with evidence of abnormal FDG uptake consis-
tent with fibrosis. An additional follow-up PET-
CT was obtained 19 months after completion of
radiotherapy.  There  was  no  abnormal  FDG
uptake in the nasopharynx or neck (Figure 1).
No pathologically enlarged lymph nodes were
seen in the cervical or supraclavicular regions.
In the upper abdomen, two areas of abnormal
FDG uptake were seen in the region of the duo-
denum (not shown). Endoscopy was performed
which demonstrated a duodenal ulcer. Biopsy
showed recurrent IDDCT 20 months after com-
pletion of his initial therapy. 
Salvage treatment and response
The patient’s duodenal disease was treated
with radiotherapy using a 3 dimensional con-
formal technique to deliver 54 Gy in 27 frac-
tions. Follow-up PET-CT scan two months after
salvage radiotherapy and 23 months after ini-
tial therapy to the nasopharynx primary tumor
showed  no  active  disease  in  any  previously
irradiated  sites.  Follow-up  nasopharyngeal
endoscopy demonstrated no residual lesion 23
months after treatment. 
Discussion
Dendritic cells are a heterogeneous group of
non-lymphoid, non-phagocytic immune acces-
sory  cells  present  in  lymphoid  and  non-lym-
phoid organs. Several types of dendritic cells
are known including follicular, interdigitating,
and Langerhans’ cells.
1 Each cell type provides
structural  and  functional  support  of  the
microenvironment  within  lymphoid  tissue.
Follicular dendritic cells (FDC) belong to the
accessory immune system and typically reside
in lymphoid follicles. They participate in the
immune  response  by  acting  as  antigen  pre-
senting cells and by playing a major role in the
humoral  immune  response.
2 Interdigitating
dendritic cells (IDC) are antigen presenting
cells characterized by interdigitating cellular
junctions.
3 These cells typically reside in the T-
cell areas of peripheral lymphoid tissue includ-
ing Waldeyer’s ring, splenic periarteriolar lym-
phoid  sheaths,  and  mucosa-associated  lym-
phoid  tissue  (MALT).  Langerhans’  cells  are
also antigen presenting cells, residing in lym-
phoid tissue predominantly in the skin.
4,5
Dendritic  cell  neoplasms  are  classified  by
the  International  Lymphoma  Study  Group
(ILSG) into four categories based on immuno-
phenotypic  groups:  interdigitating  dentritic
cell  tumors/sarcomas  (IDDCT/S),  follicular
dendritic  cell  tumors/sarcomas  (FDCT/S),
Langerhans’  cell  tumors  (LCT),  and
Langerhans’ cell sarcomas (LCS).
6 Generally,
IDDCT/S is thought to be a disease entity of
older individuals with a mean age at diagnosis
of  71.2  years.
7 Aggressive  tumor  behavior  is
seen  in  approximately  one  third  of  cases.
7
IDDCT/S  typically  manifest  with  lym-
phadenopathy and have been reported in the
cervical,  axillary,  inguinal,  and  regional
parotid  lymph  nodes.
7,8 Extranodal  locations
have been reported in the tonsils, nasophar-
ynx, spleen, lung, bladder, testis, breast, and
bone marrow.
3,7-10
FDCT/S predominantly has been document-
ed  to  arise  in  lymph  nodes
8,11 with  behavior
similar to a low-grade sarcoma rather than a
lymphoma.
11,12 Nodal  involvement  typically
presents in the cervical or axillary lymph nodes
of  young  to  middle-aged  adults.  Extranodal
locations have been reported throughout the
body, most commonly occurring in the tonsil,
nasopharynx,  pancreas,  peripancreatic  and
peritoneal tissues.
13-17 Extranodal locations are
under-recognized most likely due to the diag-
nosis not being considered or recognized as
demonstrated in a recent publication review-
ing 46 cases suspicious for extranodal FDCT/S
reported that 15 cases (33%) were misdiag-
nosed at the time of initial evaluation.
18
Langerhans’ cells, are normally present in
the  suprabasal  squamous  epithelium  of  the
skin and mucous membranes. LCT represents
a proliferation of Langerhans’ cells with malig-
nant features, typically occurring in the third
to fourth decade of life. Multi-organ involve-
ment has been reported including skin, lymph
nodes, lung, bone marrow and brain, with skin
and  lymph  nodes  being  the  most  frequently
involved organ systems.
14
Generally,  most  dendritic  neoplasms  are
considered  low  or  intermediate-grade  malig-
nancies
11,19 with the exception of IDDCT/S in
which  one  third  of  cases  display  aggressive
behavior.
7 Various modalities have been imple-
mented for the treatment of dendritic cell neo-
plasms  including  surgery,  primary  radiation
therapy, systemic chemotherapy, or a combina-
tion  of  these  modalities.  No  consensus  has
been reached as to the most appropriate treat-
ment regimen due to the variation in reported
treatment  methodologies  with  limited  pub-
lished outcome data. 
In patients with localized disease, the main-
stay of treatment has been surgical resection
with  or  without  adjuvant  treatment.  Shia  et
al.
18 retrospectively reviewed 46 cases of extra-
nodal FDCS in which 44 of 46 patients under-
went  surgical  resection.  Local  recurrence
occurred in 26% of cases at a median of 15
months post resection. Forty-three percent of
patients developed local and/or distant recur-
rence  after  initial  treatment.  Chan  et  al.
11
reviewed 17 cases of FDCS, in which 14 of 17
patients  underwent  surgical  resection.  Local
recurrence occurred in 42% of patients at a
median of 15 months. Six patients developed
distant  metastatic  disease,  including  4
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Figure  1.  PET-CT
imaging of pre- and
post-radiation FDG
uptake  of  the  pri-
mary  tumor  and
nodal sites.
Figure  2.  H&E  stain  of  the  primary
nasopharyngeal  tumor.  The  inlaid  box
shows diffuse CD43 positivity.
A. Pre-treatment B. 1 month post-RT C. 19 months post-RT[Rare Tumors 2010; 2:e9] [page 29]
patients who also had local recurrence.
Combined modality approaches have been
sporadically reported with inconclusive bene-
fits.  Adjuvant  radiation  therapy  has  been
shown to increase disease free intervals but
has failed to show benefit in preventing local
recurrences  or  distant  metastasis.
11,18
Combined  treatment  with  radiation  and
chemotherapy has been utilized with limited
survival  benefit,
11,18 but  some  studies  have
reported a benefit for combined radiation and
chemotherapy in preventing local recurrence
in  incompletely  excised  or  recurrent
lesions.
12,19
Despite  a  possible  benefit  with  radiation
therapy in an adjuvant setting, the role of pri-
mary radiation is less clear. Complete and par-
tial responses have been reported in a small
number of patients. Progression free intervals
ranging from five to 12 months and disease
free intervals up to 4.5 years have been report-
ed.
7,11 Typical radiation doses that have been
reported range from 50 Gy to 60 Gy.
7,11,17 In our
patient, the nasopharyngeal tumor as well as
the retropharyngeal lymph nodes and bilateral
involved cervical nodes were treated to 66 Gy,
resulting in a complete clinical response in the
primary tumor based on MRI and PET-CT 23
months after treatment. The duodenal lesion
was treated with 54 Gy, achieving a complete
clinical response by both PET-CT and on endo-
scopic  evaluation  three  months  after  treat-
ment. Dendritic cell tumors of the head and
neck region are well documented in the litera-
ture with a paucity of cases reported arising in
the nasopharynx. Biddle et al.
20 reviewed extra-
nodal FDCS of the head and neck, in which 3 of
19 cases were located in the nasopharynx. In
all cases, surgery was implemented as the pri-
mary treatment modality. Radiation was used
in  an  adjuvant  setting  in  8  of  the  reported
cases in the setting of residual tumor after sur-
gery. Disease free intervals in patients treated
with a multimodality approach ranged from ten
months to 4.5 years. IDDCT/S of the head and
neck region are an even rarer entity. Gaertner
et al.
7 reviewed 29 cases of IDDCS reported in
the literature and identified 5 tumors located
in the head and neck region (3 lymph nodes,
one tonsil, one nasopharynx). Therapy gener-
ally consisted of surgery followed by multia-
gent chemotherapy. Radiation therapy alone or
in  the  adjuvant  setting  was  used  in  several
cases. In the cohort of patients, 9 died within
one year of diagnosis and 7 patients were alive
with stable or progressive disease at the end of
treatment.  With  a  limited  number  of  cases,
non-uniformity  in  treatment  regimens  and
short follow-up, there is no standard recom-
mendation for treatment. 
Conclusions
Dendritic cell tumors of the head and neck
are  rare  tumors,  especially  if  they  arise  in
extra-nodal  locations.  IDDCT/S  represents  a
variant with more aggressive behavior and a
predilection  for  widespread  disease.  Multi-
modality treatment likely has some benefit in
improving disease free survival and progres-
sion free survival. The role of primary radia-
tion in the management of this disease entity
remains to be determined. Our patient repre-
sents one of the few reported cases of IDDCT/S
of the nasopharynx with lymph node involve-
ment  who  had  a  complete  clinical  response
with demonstrated local control at 23 months
following primary radiation therapy. IDDCT/S
is  a  radiosensitive  disease  entity  and  high-
dose radiation therapy appears to be a reason-
able treatment option for patients with unre-
sectable disease.
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